Masimo (NASDAQ:MASI) Releases FY 2025 Earnings Guidance

Masimo (NASDAQ:MASI) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 5.100-5.400 for the period, compared to the consensus estimate of 4.690. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MASI. Piper Sandler raised their price target on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Wells Fargo & Company raised their price target on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Raymond James lifted their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $194.80.

Masimo Stock Down 0.6 %

Shares of NASDAQ MASI opened at $174.52 on Friday. The company has a market capitalization of $9.42 billion, a P/E ratio of 120.36 and a beta of 1.04. Masimo has a 52-week low of $101.61 and a 52-week high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The company’s 50 day moving average price is $174.95 and its 200-day moving average price is $156.02.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. The firm had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Equities analysts forecast that Masimo will post 4.1 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.